AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Collegium Pharmaceutical announces the sale of AllerNaze to Lupin.
Collegium Pharmaceutical Inc announced that Lupin has acquired all worldwide rights to AllerNaze (triamcinolone acetonide, USP) Nasal Spray, 50 mcg. AllerNaze is an aqueous based intranasal steroid (INS) product indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children 12 years of age and older that was approved by the US Food and Drug Administration (FDA) in Jan 2009. AllerNaze will compete in the approximately $2.5 M a year US market for INS products for the treatment of allergic rhinitis. …
-
- Collegium Pharmaceutical announces FDA approval of AllerNaze, a nasal inhaled...
-
News wire article from: Chemical Business Newsbase
January 8, 2009
700+ words
-
- Collegium Pharmaceutical Inc announces Notice of Allowance for US Patent...
-
News wire article from: Chemical Business Newsbase
May 26, 2009
700+ words
-
- Collegium Pharmaceutical announces successful completion of proof of concept...
-
News wire article from: Chemical Business Newsbase
March 5, 2007
700+ words
-
- Collegium acquires Tri-Nasal Nasal Spray for allergic rhinitis from Muro...
-
News wire article from: Asia Africa Intelligence Wire
October 7, 2003
700+ words
-
- CORPORATE: Lupin buys global rights for nasal steroid from Collegium.
-
News wire article from: Business Line
July 2, 2009
700+ words
